Deals Of The Week: Roche/Illumina, GSK/HGSI, Sanofi/MJFF
Executive Summary
After a few months of sometimes-testy back and forth, Illumina seemingly has successfully fended off Roche’s hostile offer. But Roche is unlikely to give up on the sequencing tool maker entirely.
You may also be interested in...
Only Alli Remains After Glaxo’s OTC Transaction With Aspen
GlaxoSmithKline sells 19 OTC brands – worth about 1% of its consumer healthcare business – outside the U.S., Canada and Europe to South African firm Aspen Pharmacare. Weight-loss drug alli is GSK’s final remaining non-core OTC following the $263 million deal.
Roche Pounces On Market-Weakened Illumina
Roche’s $5.7 billion hostile takeover offer for Illumina is opportunistic as well as strategic. It is a validation of Illumina’s long-term growth potential but also takes advantage of a depressed stock price due to the global economic slowdown and cutbacks in government funding that have hurt Illumina and other providers of gene sequencing instrumentation.
Genomics Through The Lens Of Precompetitive Data Sharing
With low-cost whole genome sequencing on the horizon, issues around acquiring and assessing large data sets of sequence information are front and center. The value proposition is also shifting, from the means of acquiring data to their interpretation. But finding a sustainable business model around data analysis and clinical services is far from straightforward.